Abstract
In this study, we describe the effects produced by the retroviral transduction of human type I consensus IFN (CIFN) coding sequence into the 8863 and 1B6 human melanoma cell lines, derived from a metastatic and a primary human melanoma, respectively. Melanoma cell lines producing approximately 103 IU/ml of IFN were obtained. Interestingly, cisplatin treatment of IFN-producing 8863 and 1B6 melanoma cells resulted in a three- to four-fold increase in the percentage of apoptotic cells with respect to similarly treated parental or control-transduced cell cultures. A similar effect, although less intense, was caused by cultivation of parental melanoma cells in the presence of exogenous CIFN. The increased susceptibility of the IFN-producing melanoma cell lines to cisplatin-induced apoptosis was associated with an IFN-dependent accumulation of p53, which also correlated with a decrease in Bcl-2 expression. Addition of exogenous CIFN to parental melanoma cells resulted in similar although weaker modulations of p53 and Bcl-2 expression. Cisplatin administration to nude mice bearing 3-day-old IFN-producing 8863 tumors resulted in complete tumor regression, while only a partial tumor inhibition was observed upon cisplatin treatment of mice bearing parental or control-transduced 8863 tumors. Starting the cisplatin treatment 7 days after tumor cell injection still resulted in a stronger inhibition of tumor growth in the mice bearing IFN-producing 8863 tumors as compared with parental tumor-bearing mice. A comparable therapeutic effect was obtained after repeated peritumoral administration of 103 IU of exogenous CIFN and cisplatin treatment. Interestingly, a spontaneous tumor regression was observed in nude mice injected with IFN-producing 1B6 cells, in contrast to the progressive tumor growth occurring in mice receiving a similar inoculum of the parental or control-transduced 1B6 melanoma cells. Repeated peritumoral administration of 103 IU of exogenous CIFN to mice bearing parental 1B6 tumors caused only a transient inhibition of tumor growth. These results indicate that type I IFN gene transfer is an effective approach for suppressing the tumorigenic phenotype of human melanoma cells and for increasing the efficacy of anticancer drugs. These observations, together with our previous findings showing the importance of IFN-α–T cell interactions in the generation of an antitumor response in mouse models, underline the interest of using type I IFN in gene therapy strategies for the treatment of human melanoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cohen GL, Falkson CI . Current treatment options for malignant melanoma Drugs 1998 55: 791–799
Kirkwood JM et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 1996 14: 7–17
Weiss K . Safety profile of interferon-alpha therapy Semin Oncol 1998 25: 9–13
Hussein AM . The potential application of gene transfer in the treatment of patients with cancer: a concise review Cancer Invest 1996 14: 343–352
Pfeffer LM et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons Cancer Res 1998 58: 2489–2499
Belardelli F . Role of interferons and other cytokines in the regulation of the immune response APMIS 1995 103: 161–179
Ferrantini M et al. Alpha1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells Cancer Res 1993 53: 1107–1112
Ferrantini M et al. IFN-alpha1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma producing TS/A cells J Immunol 1994 153: 4604–4615
Kaido T et al. IFN-α1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice Int J Cancer 1995 60: 1–9
Gabriele L et al. The local and systemic response of mice to interferon-α1 transfected Friend Leukemia cells Am J Pathol 1995 147: 445–460
Sarkar S et al. Injection of irradiated melanoma genetically modified to secrete IFN-α causes regression of an established tumor Int J Oncol 1995 7: 17–24
Tüting T et al. Interferon-α gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models Gene Therapy 1997 4: 1053–1060
Rozera C et al. Murine IFN-α1 gene transduced ESb tumor cells are rejected by host-mediated mechanisms despite the resistance of the parental tumor to IFN-α/β therapy Cancer Gene Ther 1999 6: 246–253
Belldegrun A et al. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines J Natl Cancer Inst 1993 85: 207–216
Cao X et al. Treatment of human hepatocellular carcinoma by fibroblasts-mediated human interferon alpha gene therapy in combination with adoptive chemoimmunotherapy J Cancer Res Clin Oncol 1995 121: 457–462
Wang J et al. Treatment of leukemia with fibroblasts-mediated interferon-alpha gene therapy alone or in combination with doxorubicin Leukemia Res 1996 20: 379–384
Zhang JF et al. Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression Cancer Gene Ther 1996 3: 31–38
Santodonato L et al. Cure of mice with established metastatic Friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-α1 and Herpes simplex thymidine kinase followed by ganciclovir Hum Gene Ther 1996 7: 1–10
Santodonato L et al. Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-α and HSVTK: perspectives for the generation of cancer vaccines Gene Therapy 1997 4: 1246–1255
Sulé-Suso J et al. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes Eur J Immunol 1995 25: 2737–2742
Arienti F et al. Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes Hum Gene Ther 1994 5: 1139–1150
Nguyen H, Lin R, Hiscott J . Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins Oncogene 1997 15: 1425–1435
Favrot M, Coll J-L, Louis N, Negoescu A . Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy Gene Therapy 1998 5: 728–739
Li G et al. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent Melanoma Res 1998 8: 17–23
Davol PA, Goulette FA, Frackelton AR Jr, Darnowsky JW . Modulation of p53 expression by human recombinant interferon-α2a correlates with abrogation of cisplatin resistance in a human melanoma cell line Cancer Res 1996 56: 2522–2526
Hansen R, Oren M . p53; from inductive signal to cellular effect Curr Opin Genet Dev 1997 7: 46–51
Strasser A, Huang DCS, Vaux DL . The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy Biochim Biophys Acta 1997 1333: F151–F178
Wadler S . The role of interferons in the treatment of solid tumors Cancer 1992 70: 949–958
Thomas H, Balkwill FR . Effects of interferons and other cytokines on tumors in animals: a review Pharmacol Ther 1991 52: 307–330
Tanaka N et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1 Cell 1994 77: 829–839
Kumar A et al. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-κB EMBO J 1997 16: 406–416
Tamura T et al. Interferon-gamma induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line Biochem Biophys Res Commun 1996 229: 21–26
Giandomenico V et al. Retinoic acid and IFN inhibition of cell proliferation is associated with apoptosis in squamous carcinoma cell lines: role of IRF-1 and TGase II-dependent pathways Cell Growth Differ 1997 8: 91–100
Kumar A et al. Defective TNF-α-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases Science 1997 278: 1630–1632
Lotem J, Sachs L . Cytokine suppression of protease activation in wild-type p53-dependent and p53-independent apoptosis Proc Natl Acad Sci USA 1997 94: 9349–9353
Belardelli F, Gresser I . The neglected role of type I interferon in the T-cell response: implications for its clinical use Immunol Today 1996 17: 369–372
Tough DF, Borrow P, Sprent J . Induction of bystander T cell proliferation by viruses and type I interferon in vivo Science 1996 272: 1947–1950
Belardelli F et al. Induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after injection of tumor cells expressing IFN-α1 into syngeneic mice Cancer Res 1998 58: 5795–5802
Romagnani S . Induction of Th1 and Th2 responses: a key role for the ‘natural’ immune response? Immunol Today 1992 13: 379–381
Rogge L et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells J Exp Med 1997 485: 825–830
Luft T et al. Type I IFN enhance the terminal differentiation of dendritic cells J Immunol 1998 161: 1947–1953
Paquette RL et al. Interferon-α and granulocyte–macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells J Leukoc Biol 1998 64: 358–367
Tuting T et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α J Immunol 1998 160: 1139–1147
Gnjatic S et al. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas J Immunol 1998 160: 328–333
McCarty TM et al. Targeting p53 for adoptive T-cell immunotherapy Cancer Res 1998 58: 2601–2605
Miller AD, Rosman GJ . Improved retroviral vectors for gene transfer and expression BioTechniques 1989 7: 980–984
Alton K et al. Production, characterization and biological effects of recombinant DNA derived human IFN-α and IFN-γ analogs. In: De Maeyer E, Schellenkens H (eds) The Biology of the Interferon System Elsevier: Amsterdam 1983 119–128
Markowitz D, Goff S, Bank A . A safe packaging line for gene transfer: separating viral genes on two different plasmids J Virol 1988 62: 1120–1124
Markowitz D, Goff S, Bank A . Construction and use of a safe and efficient amphotropic packaging cell line Virology 1988 167: 400–406
Malorni W, Rivabene R, Santini MT, Donelli G . N-acetylcysteine inhibits apoptosis and decreases viral particles in HIV-chronically infected U937 cells FEBS Lett 1993 327: 75–78
Acknowledgements
This work was supported in part by grants from the ‘Associazione Italiana Ricerca sul Cancro’ (Milan) and the Italy–USA Special Project on ‘Therapy of tumors’. M Mecchia is the recipient of a fellowship from the ‘Fondazione Italiana per la Ricerca sul Cancro’.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mecchia, M., Matarrese, P., Malorni, W. et al. Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha. Gene Ther 7, 167–179 (2000). https://doi.org/10.1038/sj.gt.3301059
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301059
Keywords
This article is cited by
-
Gene therapy in interventional pulmonology: Interferon gene delivery with focus on thoracic malignancies
Current Respiratory Care Reports (2012)
-
Antiviral action of the tumor suppressor ARF
The EMBO Journal (2006)
-
Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma
Laboratory Investigation (2006)
-
Interferon α2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers
Cancer Gene Therapy (2001)